SEC Form 4 · accession 0001209191-18-005841
Yarrow Bioscience, Inc. · YARW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
venBio Global Strategic Fund II L.P.
10% Owner
Period of report
Jan 25, 2018
Accepted (ET)
Jan 29, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566044
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 25, 2018 | P | 265,000 | $17.00 | A | 265,000 | D | |
| Common StockF1 | Jan 29, 2018 | C | 1,196,552 | — | A | 1,461,552 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Preferred StockF1 | — | Jan 29, 2018 | C | 3,227,700 | D | — | — | Common Stock | 1,196,552 | 0 | D |
Explanation of responses
- F1Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.